By Denny Jacob
EyePoint Pharmaceuticals shares slide 32% after disclosing that topline results from a Phase 2 clinical trial evaluating Duravyu in non-proliferative diabetic retinopathy didn't meet the pre-specified primary endpoint.
Shares were trading around $13.46 after resuming trading at 7:30 a.m. ET following a halt at 6:55 a.m. ET. The stock is down 15% on the year so far.
Non-proliferative diabetic retinopathy is an early stage of diabetic retinopathy, a leading cause of blindness in working age adults, in which symptoms may be mild or nonexistent.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
05-06-24 0805ET